GALECTIN THERAPEUTICS INC (GALT) competitors & alternatives
Health Care · NASDAQ
GALECTIN THERAPEUTICS INC (GALT)'s top competitors and alternatives — its most similar public companies — include MADRIGAL PHARMACEUTICALS, INC. (MDGL), Viking Therapeutics (VKTX), SAVARA INC (SVRA), ALECTOR INC (ALEC), AN2 THERAPEUTICS INC (ANTX), PepGen Inc. (PEPG), SPRUCE BIOSCIENCES INC (SPRB), CONTEXT THERAPEUTICS INC (CNTX), AQUESTIVE THERAPEUTICS INC (AQST), OMEROS CORP (OMER), SOLID BIOSCIENCES INC (SLDB) and XERIS BIOPHARMA HOLDINGS INC (XERS). These are GALECTIN THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GALT competitors & alternatives
-
MADRIGAL PHARMACEUTICALS, INC.MDGLHealth Care
Madrigal is a commercial-stage biotech company exclusively focused on Rezdiffra, the first FDA-approved treatment for MASH with moderate-to-advanced fibrosis,…
$537.65 (as of 2026-07-22) · market cap $12.4B
-
Viking TherapeuticsVKTXHealth Care
Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market…
$37.31 (as of 2026-07-22) · market cap $4.3B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
ALECTOR INCALECHealth Care
An early-stage biotech company developing novel therapeutic candidates for neurodegenerative diseases through preclinical research and clinical trials.
$1.53 (as of 2026-07-22) · market cap $169M
-
AN2 THERAPEUTICS INCANTXHealth Care
AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other…
$4.89 (as of 2026-07-22) · market cap $176M
-
PepGen Inc.PEPGHealth Care
PepGen is a biotechnology company developing novel oligonucleotide therapies that use proprietary peptide-based delivery technology to treat severe…
$1.92 (as of 2026-07-22) · market cap $133M
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
-
OMEROS CORPOMERHealth Care
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem…
$9.84 (as of 2026-07-22) · market cap $703M
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
Not quite? Describe exactly what you want →
Peers are GALECTIN THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: GALECTIN THERAPEUTICS INC (GALT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.